Literature DB >> 11370428

[Tuberculosis screening coverage of immigrants: marked attrition in follow-up screenings].

R Bwire, S Verver, J A Année-van Bavel, P Kouw, S T Keizer, M W Borgdorff.   

Abstract

OBJECTIVE: To estimate the coverage of bi-annual follow-up screening for tuberculosis amongst immigrants, excluding asylum seekers.
DESIGN: Retrospective cohort study.
METHODS: Participation in bi-annual chest X-ray screening during the first 18 months was recorded for immigrants who underwent entry screening in 1996 in the following Dutch municipal health services (MHS's): Zuid-Kennemerland (Haarlem), Flevoland (Lelystad), Midden-Brabant (Tilburg) en West-Friesland (Hoorn). The number of immigrants that had left the country before the subsequent screening was taken into account in the Zuid-Kennemerland MHS data on screening coverage.
RESULTS: Of the 2147 immigrants who underwent entry screening in 1996 (48% men and 52% women; 68% aged 15-34 years), 1075 (50%; range: 29-76) returned for the first follow-up screening and 620 (29%; 21-61) returned for the second. In MHS Zuid-Kennemerland, 113 of the 777 immigrants who had a chest X-ray at entry had left the country before the first follow-up screening, and another 89 had left before the second. Of the remaining persons, who were probably still in the Netherlands, 454 (68%; 454/777 = 58%) returned for the first follow-up screening, and 166 (29%; 166/777 = 21%) returned for the second.
CONCLUSION: The coverage of screening for tuberculosis in immigrants decreased after the obligatory entry screening, even when corrected for those who left the country.

Entities:  

Mesh:

Year:  2001        PMID: 11370428

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

1.  High incidence of pulmonary tuberculosis persists a decade after immigration, The Netherlands.

Authors:  Annelies M Vos; Abraham Meima; Suzanne Verver; Caspar W N Looman; Vivian Bos; Martien W Borgdorff; J Dik F Habbema
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.